Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Reuters

2025/09/04

Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564822375"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564822375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564822375?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564822375","market":"fut","top_or_hot":-1,"title":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMUX","symbol_name":"Immunic, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7QLRpT:1","article_id":"2564822375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564822375","pubTimestamp":1756981848,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis  in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium , an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMUX":"Immunic, Inc.","BK4139":"生物科技"},"translate_title":"Immunic Inc.在ECTRIMS 2025上宣布维多氟地莫斯钙治疗进行性多发性硬化症的新临床研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    \n\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}